Italia markets open in 4 hours 5 minutes

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
12,59+0,76 (+6,42%)
Alla chiusura: 04:00PM EDT
13,17 +0,58 (+4,61%)
Dopo ore: 06:06PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente11,83
Denaro12,04 x 900
Lettera13,16 x 1800
Min-Max giorno11,79 - 12,67
Intervallo di 52 settimane9,59 - 73,03
Media Volume1.688.709
Beta (5 anni mensile)2,06
Rapporto PE (ttm)N/D
EPS (ttm)-2,73
Prossima data utili02 ago 2022 - 08 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A32,23
  • GlobeNewswire

    Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

    TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, “Editas Medicine”), a leading genome editing company, today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell a

  • GlobeNewswire

    Editas Medicine Reports Inducement Grants to New Chief Executive Officer

    CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed President and Chief Executive Officer, Gilmore O’Neill, M.B., M.M.Sc. As previously announced, Dr. O’Neill joined the Company on June 1, 2022, in his new role. In connection with Dr. Gilmore’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. O’Neill as an

  • GlobeNewswire

    Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

    SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo persistence in an ovarian cancer mouse model CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present data later today on its SLEEK (SeLection by Essential- gene Exon Knock-in) gene editing technology during the New Gene Editin